journal article·2019-11-19Open access

Microfluidics as tool to prepare size-tunable PLGA nanoparticles with high curcumin encapsulation for efficient mucus penetration

Nashrawan Lababidi, Valentin Sigal, Aljoscha Koenneke, Konrad Schwarzkopf, Andreas Manz, Marc Schneider

Abstract

Great challenges still remain to develop drug carriers able to penetrate biological barriers (such as the dense mucus in cystic fibrosis) and for the treatment of bacteria residing in biofilms, embedded in mucus. Drug carrier systems such as nanoparticles (NPs) require proper surface chemistry and small size to ensure their permeability through the hydrogel-like systems. We have employed a microfluidic system to fabricate poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with a muco-penetrating stabilizer (Pluronic), with a tunable hydrodynamic diameter ranging from 40 nm to 160 nm. The size dependence was evaluated by varying different parameters during preparation, namely polymer concentration, stabilizer concentration, solvent nature, the width of the focus mixing channel, flow rate ratio and total flow rate. Furthermore, the influence of the length of the focus mixing channel on the size was evaluated in order to better understand the nucleation–growth mechanism. Surprisingly, the channel length was revealed to have no effect on particle size for the chosen settings. In addition, curcumin was loaded (EE% of ≈68%) very efficiently into the nanoparticles. Finally, the permeability of muco-penetrating PLGA NPs through pulmonary human mucus was assessed; small NPs with a diameter of less than 100 nm showed fast permeation, underlining the potential of microfluidics for such pharmaceutical applications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Cystic Fibrosis Research Advances · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. 10.1016/j.vaccine.2013.11.06910.1016/j.vaccine.2013.11.069 ↗
2. 10.1586/14760584.6.5.79710.1586/14760584.6.5.797 ↗
3. 10.1038/nrd261410.1038/nrd2614 ↗
4. 10.1016/j.addr.2007.04.00810.1016/j.addr.2007.04.008 ↗
5. 10.1016/j.addr.2008.11.00210.1016/j.addr.2008.11.002 ↗
6. 10.1016/j.carbpol.2017.02.06510.1016/j.carbpol.2017.02.065 ↗
7. 10.1002/1521-3773(20011119)40:22<4128::aid-anie4128>3.0.co;2-s10.1002/1521-3773(20011119)40:22<4128::aid-anie4128>3.0.co;2-s ↗
8. 10.1016/j.addr.2008.02.01310.1016/j.addr.2008.02.013 ↗
9. 10.1021/bm201226x10.1021/bm201226x ↗
10. 10.1073/pnas.060861110410.1073/pnas.0608611104 ↗
11. 10.1002/anie.20100684910.1002/anie.201006849 ↗
12. 10.1016/j.jconrel.2014.06.05510.1016/j.jconrel.2014.06.055 ↗
13. 10.1021/acs.biomac.5b0148010.1021/acs.biomac.5b01480 ↗
14. 10.2217/nnm.12.12910.2217/nnm.12.129 ↗
15. 10.1016/j.ijpharm.2017.09.01810.1016/j.ijpharm.2017.09.018 ↗
16. 10.1016/j.addr.2017.12.01010.1016/j.addr.2017.12.010 ↗
17. 10.1073/pnas.090599810610.1073/pnas.0905998106 ↗
18. 10.1021/acs.biomac.6b0016410.1021/acs.biomac.6b00164 ↗
19. 10.1016/j.tcb.2011.06.00210.1016/j.tcb.2011.06.002 ↗
20. 10.1016/j.copbio.2018.03.01010.1016/j.copbio.2018.03.010 ↗
21. 10.1016/j.jconrel.2018.07.00110.1016/j.jconrel.2018.07.001 ↗
22. 10.1016/j.ijpharm.2018.12.04810.1016/j.ijpharm.2018.12.048 ↗
23. 10.1016/j.addr.2017.10.00910.1016/j.addr.2017.10.009 ↗
24. 10.1016/j.ejpb.2015.11.00310.1016/j.ejpb.2015.11.003 ↗
25. 10.2174/221030310466614022200210110.2174/2210303104666140222002101 ↗
26. 10.1016/s0169-409x(97)00048-310.1016/s0169-409x(97)00048-3 ↗
27. 10.1016/j.nano.2011.05.01610.1016/j.nano.2011.05.016 ↗
28. 10.1016/s0168-3659(97)00106-510.1016/s0168-3659(97)00106-5 ↗
29. 10.1081/ddc-10010125510.1081/ddc-100101255 ↗
30. 10.1081/ddc-10010219710.1081/ddc-100102197 ↗
31. 10.1016/s0168-3659(98)00116-310.1016/s0168-3659(98)00116-3 ↗
32. 10.1038/nature0505810.1038/nature05058 ↗
33. 10.1007/s11095-015-1681-710.1007/s11095-015-1681-7 ↗
34. 10.1016/j.ijpharm.2016.10.02510.1016/j.ijpharm.2016.10.025 ↗
35. 10.1080/17425247.2016.119315110.1080/17425247.2016.1193151 ↗
36. 10.1021/nl801736q10.1021/nl801736q ↗
37. 10.1038/nnano.2012.16810.1038/nnano.2012.168 ↗
38. Jurenka · Alternative Medicine Review · 2009 · 14 · 141
39. 10.1016/j.ejpb.2017.12.01710.1016/j.ejpb.2017.12.017 ↗
40. 10.1038/nrd149410.1038/nrd1494 ↗
41. 10.1039/c5nr03543k10.1039/c5nr03543k ↗
42. 10.1021/ja806586v10.1021/ja806586v ↗
43. 10.1016/j.addr.2011.04.00510.1016/j.addr.2011.04.005 ↗
44. 10.1088/0957-4484/23/37/37560210.1088/0957-4484/23/37/375602 ↗
45. 10.1016/0378-5173(89)90281-010.1016/0378-5173(89)90281-0 ↗
46. 10.1016/j.apt.2017.09.00510.1016/j.apt.2017.09.005 ↗
47. 10.1021/bm501419z10.1021/bm501419z ↗
48. 10.1021/acsnano.5b0689010.1021/acsnano.5b06890 ↗
49. 10.1002/adma.20140540810.1002/adma.201405408 ↗
50. 10.1016/j.colsurfa.2013.08.05610.1016/j.colsurfa.2013.08.056 ↗
51. 10.1002/mabi.20140021410.1002/mabi.201400214 ↗
52. 10.3791/5875710.3791/58757 ↗
53. 10.1016/j.ijpharm.2009.04.04910.1016/j.ijpharm.2009.04.049 ↗
54. 10.1016/j.jmbbm.2017.03.00910.1016/j.jmbbm.2017.03.009 ↗
55. 10.1529/biophysj.104.05450210.1529/biophysj.104.054502 ↗